Clinical trials: Oligoprogression
Oligometastatic Disease, Oligoprogression
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs.
- Conditions
- Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
- Trial name
- NCT05784428
- Testing
- Single fraction SABR, Multiple fraction SABR, QoL reporting alone
- Where
- 14 sites in Canada, Ireland
- Volunteers
- 598 people
- Sponsor
- Robert Olson
HER2-mutated Advanced Non-small Cell Lung Cancer With Oligoprogression
A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer
A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined with Radiotherapy in Patients with HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07781202
- Testing
- Trastuzumab Rezetecan combined with radiotherapy
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Brain Metastasis, Oligoprogression
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Brain metastases (BM) are a common systemic cancer manifestation which incidence increases. Therapeutic options include whole-brain radiotherapy (WBRT), surgery, and stereotactic radiosurgery (SRS).
- Trial name
- OligoBM-01 (NCT05102747)
- Testing
- Hypofractionated SRT (stereotactic radiotherapy), Historical single-dose SRS (stereotactic radiosurgery)
- Where
- 15 sites in France
- Volunteers
- 504 people
- Sponsor
- Centre Francois Baclesse
NSCLC, EGFR Positive Non-small Cell Lung Cancer
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
Study Objectives are: To assess the safety of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after concomitant osimertinib and…
- Conditions
- NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression
- Trial name
- ROSE (NCT05089916)
- Testing
- Osimertinib, Radiotherapy
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- AIO-Studien-gGmbH
Oligoprogression, Oligometastatic Disease
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
- Conditions
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- Trial name
- NCT06918951
- Testing
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Where
- Canada
- Volunteers
- 194 people
- Sponsor
- British Columbia Cancer Agency
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
SMC Radiation Oncology SABR Cohort for Oligometastasis
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1.
- Conditions
- Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
- Trial name
- SABR-OMOP (NCT07121335)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma, Oligoprogression
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Approximately 70% of hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage, with no opportunity for curative treatments. For these patients, systemic therapies are the main treatment modalities.
- Trial name
- NCT06592612
- Testing
- SBRT and second-line systemic therapy, Second-line systemic therapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Metastatic Breast Cancer, Oligoprogression
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
Recent advances in systemic therapy have facilitated improved progression-free survival (PFS) and treatment tolerability in metastatic breast cancer patients (MBC).
- Trial name
- STAR-B (NCT06489821)
- Testing
- Stereotactic body radiotherapy
- Volunteers
- 36 people
- Sponsor
- Juravinski Cancer Center